A report suggests the cause behind different outcomes among patients with diffuse large B-cell lymphoma who relapse, highlighting that patients whose cancer relapses shortly after treatment tend to have worse responses to additional chemotherapy-based treatment.

Positive data from the phase 3 EV-302 trial of enfortumab vedotin with pembrolizumab in locally advanced or metastatic urothelial cancer have shifted the landscape.

The growing number of clinical trials testing neoadjuvant immunotherapy with or without chemotherapy has opened up new possibilities for treating locally advanced solid tumors.

In the first article of a 2-part series, Pankit Vachhani, MD, discusses what makes classical cases of myeloproliferative neoplasms unique and how ruxolitinib impacts their reduction of spleen volume.

Combining the glutaminase-1 inhibitor CB-839 and BCL-2 inhibitor venetoclax could be a new avenue for the treatment of diffuse large B-cell lymphoma.

Matthew Hadfield, DO, discusses his passion for early-stage clinical trials and the need for more research into immunotherapy toxicities during the third episode of Emerging Experts.

During a Targeted Oncology™ Clinical Case Forum event in partnership with the South Carolina Oncology Society, Hamza Hashmi, MD, discusses the significance of the MajesTEC-1 of the bispecific T-cell engager teclistamab for patients with relapsed/refractory multiple myeloma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Jonathan L. Kaufman, MD, discussed results of the MonumenTAL-1 trial of talquetamab in patients with heavily pretreated relapsed/refractory multiple myeloma. This is the first of 2 articles based on this event.

The investigation follows reports of T-cell malignancies after treatment with chimeric antigen receptor T-cell immunotherapies.

New guidelines for gastroenteropancreatic neuroendocrine tumors were issued by the American Society of Clinical Oncology and geared toward community oncologists who often encounter these rare and complex cases infrequently.

More work is needed in the community oncology setting to improve barriers to care and enrollment in clinical trials which are often due to geographic location, awareness, and eligibility criteria.

Based on in vitro data, pacritinib led to a 4-fold higher potency for inhibition of the hepcidin regulator ACVR1 vs momelotinib among patients with cytopenic myelofibrosis and led to an increase in red blood cell transfusion independence.

A phase 1/2 study of KSQ-001EX will commence at MD Anderson Cancer Center following this investigational new drug approval from the FDA.

Telisotuzumab vedotin demonstrated promising efficacy and safety in patients with advanced nonsquamous non–small cell lung cancer with high or intermediate c-Met expression.

At 2 separate Case-Based Roundtable events, oncologists discussed important factors that could influence their choice of frontline therapy for a patient with advanced hepatocellular carcinoma.

In the first article of a 2-part series, Hayder Saeed, MD, discusses the 5-year follow up data from the L-MIND study, which shows the continuing efficacy of tafasitamab and lenalidomide for patients with relapsed/refractory diffuse large B-cell lymphoma.

A real-world analysis found that patients with acute coronary syndrome who were also diagnosed with a hematologic malignancy had worse survival outcomes, and patients with multiple myeloma were overrepresented in the population.

CT-0525 is an ex vivo gene-modified autologous CAR-monocyte cellular therapy being evaluated for the treatment of HER2-overexpressing solid tumors.

In the phase 3 MURANO trial, there was a continued survival benefit in patients with chronic lymphocytic leukemia treated with fixed-duration venetoclax plus rituximab.

The potential of CTLA4 deletion as a strategy to improve chimeric antigen receptor T-cell efficacy was observed in a study published in Immunity.

Sandra M. Swain, MD, FACP, FASCO, discusses the potential role for HER2-directed TKIs for the treatment of patients with early-stage HER2+ breast cancer and shares insights about emerging data that could impact the future treatment landscape.

A fast track designation has been granted to zotatifin with fulvestrant, and abemaciclib for adult patients with estrogen receptor-positive/HER2-negative advanced or metastatic breast cancer.

In this companion article, Sandra M. Swain, MD, FACP, FASCO, provides insights into effective management of patients with early-stage HER2+ breast cancer and reviews recent data in the evolving treatment landscape.

Olvimulogene nanivacirepvec, an oncolytic viral-based therapy, has earned a fast track designation from the FDA in ovarian cancer resistant or refractory to platinum-based chemotherapy.

During a Targeted Oncology™ Case-Based Roundtable™ event, Pedro C. Barata, MD, MSc, and participants discussed dosing and toxicity issues related to tivozanib and lenvatinib/everolimus in a patient who has received 2 prior lines of therapy for metastatic clear cell renal cell carcinoma.